Dublin, June 18, 2025 (GLOBE NEWSWIRE) — The “Red Biotechnology Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F” has been added to ResearchAndMarkets.com’s offering.
The Red Biotechnology Market was valued at USD 421.32 Billion in 2024, and is expected to reach USD 774.15 Billion by 2030, rising at a CAGR of 10.67%
Market growth is being driven by increasing advancements in genetic engineering, the growing need for novel therapeutics targeting life-threatening diseases, and the surge in precision medicine development. Red biotechnology involves the use of living cells and biomolecular processes for therapeutic and diagnostic applications, including the production of vaccines, gene therapies, diagnostic reagents, and biopharmaceuticals. As demand for personalized treatments and disease-specific therapies continues to expand, the red biotechnology sector is positioned for significant growth across both developed and emerging markets.
Rising Demand for Biopharmaceuticals in Chronic and Rare Disease Management
The increasing prevalence of chronic and rare diseases is a major factor accelerating the demand for red biotechnology, especially in the development of biopharmaceuticals such as recombinant proteins, monoclonal antibodies, and gene therapies. These innovations are addressing unmet medical needs where traditional treatments fall short.
According to the World Health Organization (WHO), chronic illnesses – including cancer, cardiovascular diseases, diabetes, and respiratory disorders – account for approximately 74% of all global deaths. In parallel, rare diseases impact over 300 million individuals worldwide. Red biotechnology plays a vital role in the development of precision therapies for these complex health conditions, driving investment and research in this field globally.
High Development Costs and Complex Regulatory Requirements
A major challenge in the red biotechnology market is the substantial cost and complexity associated with developing advanced therapeutics such as gene therapies and biologics. The R&D process involves extensive clinical trials, strict regulatory compliance, and rigorous quality controls, often resulting in long timelines and high expenses.
According to the U.S. Congressional Budget Office (CBO), the cost of developing a single biopharmaceutical product can exceed $2.6 billion, and innovations within red biotechnology frequently surpass this due to their technical intricacies. Regulatory bodies such as the FDA and EMA impose detailed requirements for safety, efficacy, and long-term monitoring, particularly for gene-editing therapies. The variability in regulatory frameworks across different countries adds further challenges to global product launches, impacting speed to market and operational efficiency.
Expansion of Personalized Medicine and Genomics-Based Therapies
A transformative trend in the red biotechnology market is the rapid advancement of personalized medicine and genomics-driven therapies. Personalized medicine involves tailoring treatments to individual patients based on genetic, environmental, and lifestyle factors. Red biotechnology is central to this trend through the development of targeted therapies, gene-editing tools, and molecular diagnostics.
The widespread adoption of next-generation sequencing (NGS) and genomic profiling has enabled deeper understanding of disease mechanisms, supporting the creation of patient-specific treatment plans. The declining cost of genome sequencing – from nearly $100 million in 2001 to under $1,000 in 2024 – has accelerated clinical integration of genomics, propelling growth in red biotechnology applications.
Report Scope
Key Market Players:
- Pfizer, Inc.
- Takeda Pharmaceutical Company Limited
- Gilead Sciences
- Regeneron Pharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd.
- Bruker Corporation
- Merck KGaA
- Celgene Corporation
- Amgen Inc.
- Biogen Inc.
Red Biotechnology Market, By Product Type:
- Diagnostic Reagents
- Human Vaccines
- Blood Products
- Gene Recombinant Drugs
- Others
Red Biotechnology Market, By Application:
- Biopharmaceutical Production
- Gene Therapy
- Genetic Testing
- Pharmacogenomics
- Drug Discovery
- Others
Red Biotechnology Market, By End-User:
- Pharmaceutical and Biotechnology Companies
- CMO & CRO
- Research Institute
- Others
Red Biotechnology Market, By Region:
- North America
- United States
- Mexico
- Canada
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- India
- South Korea
- Japan
- Australia
- South America
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 185 |
| Forecast Period | 2024 – 2030 |
| Estimated Market Value (USD) in 2024 | $421.32 Billion |
| Forecasted Market Value (USD) by 2030 | $774.15 Billion |
| Compound Annual Growth Rate | 10.6% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/tb9wlu
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
